Top

Published in:

01-10-2009 | Original Article

Expression of annexin II in experimental abdominal aortic aneurysms

Authors: Tomoe Hayashi, Eriko Morishita, Hiroshi Ohtake, Yoshio Oda, Hidesaku Asakura, Shinji Nakao

Published in: International Journal of Hematology | Issue 3/2009

Abstract

Annexin II is a receptor of tissue-type plasminogen activator (t-PA). We have previously identified annexin II by immunolocalization in human atherosclerotic abdominal aortic aneurysms (AAAs). To investigate possible interactions between annexin II and AAA development, we examined annexin II mRNA and protein expression in a rat model of experimental AAA. AAAs were induced in rats by transient aortic infusion of elastase. The rats were divided into three groups: a saline-treated control group, a group with 15-min elastase infusion, and a group with 30-min elastase infusion. The 15-min elastase-infused group had smaller aneurysms and more preserved media than the 30-min elastase-infused group. Immunohistochemistry showed that annexin II expression was increased in the thickened intima and media of AAA rats as compared with the media of control rats. Furthermore, annexin II was colocalized with macrophages and smooth muscle cells. Quantitative real-time polymerase chain reaction showed that annexin II mRNA levels were up-regulated only in the smaller aneurysm group compared with the control group. In contrast, t-PA mRNA levels were increased in both the 15- and 30-min elastase-infused groups as compared with the control group. These results demonstrate various levels of annexin II expression within the aortic wall of rats with experimental AAAs. It has been suggested that alteration of fibrinolytic activity regulated by annexin II within the aortic wall may be associated with aneurysm formation.

Dobrin PB, Mrkvicka R. Failure of elastin or collagen as possible critical connective tissue alterations underlying aneurysmal dilatation. Cardiovasc Surg. 1994;2:484–8.PubMed

Lijnen HR. Plasmin and matrix metalloproteinases in vascular remodeling. Thromb Haemost. 2001;86:324–33.PubMed

Robbie LA, Booth NA, Brown AJ, Bennett B. Inhibitors of fibrinolysis are elevated in atherosclerotic plaque. Arterioscler Thromb Vasc Biol. 1996;16:539–45.CrossRefPubMed

Padro T, Emeis JJ, Steins M, Schmid KW, Kienast J. Quantification of plasminogen activators and their inhibitors in aortic vessel wall in relation to the presence and severity of atherosclerotic disease. Arterioscler Throm Vasc Biol. 1995;15:893–902.CrossRef

Carmeliet P, Moons L, Lijnen R, Baes M, Lemaitre V, Tipping P, et al. Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nat Genet. 1997;17:439–44.CrossRefPubMed

Knox JB, Sukhova GK, Whittemore AD, Libby P. Evidence for altered balance between matrix metalloproteinases and their inhibitors in human aortic disease. Circulation. 1997;95:205–12.CrossRefPubMed

Thompson RW, Parks WC. Role of matrix metalloproteinases in abdominal aortic aneurysms. Ann N Y Acad Sci. 1996;800:157–74.CrossRefPubMed

Curci JA, Liao S, Huffman MD, Shapiro SD, Thompson RW. Expression and localization of macrophage elastase (matrix metalloproteinase-12) in abdominal aortic aneurysms. J Clin Invest. 1998;102:1900–10.CrossRefPubMedPubMedCentral

Shireman PK, McCarthy WJ, Pearce WH, Shively VP, Cipollone M, Kwaan HC. Elevation of tissue-type plasminogen activator and differential expression of urokinase-type plasminogen activator in diseased aorta. J Vasc Surg. 1997;25:157–64.CrossRefPubMed

10.

Schneiderman J, Bordin GM, Engelberg I, Adar R, Seiffert D, Thinnes T, et al. Expression of fibrinolytic genes in atherosclerotic abdominal aortic aneurysm wall. A possible mechanism for aneurysm expansion. J Clin Invest. 1995;96:639–45.CrossRefPubMedPubMedCentral

11.

Reilly JM, Sicard GA, Lucore CL. Abdominal expression of plasminogen activators in aortic aneurysmal and occlusive disease. J Vasc Surg. 1994;19:865–72.CrossRefPubMed

12.

Hajjar KA, Jacovina AT, Chacko J. An endothelial cell receptor for plasminogen and tissue plasminogen activator. I. Identity with annexin II. J Biol Chem. 1994;269:21191–7.PubMed

13.

Cesarman GM, Guevara CA, Hajjar KA. An endothelial cell receptor for plasminogen/tissue plasminogen activator (t-PA). II. Annexin II-mediated enhancement of t-PA-dependent plasminogen activation. J Biol Chem. 1994;269:21198–203.PubMed

14.

Menell JS, Cesarman GM, Jacovina AT, McLaughlin MA, Lev EA, Hajjar KA. Annexin II and bleeding in acute promyelocytic leukemia. N Engl J Med. 1999;340:994–1004.CrossRefPubMed

15.

Falcone DJ, Borth W, Khan KM, Hajjar KA. Plasminogen-mediated matrix invasion and degradation by macrophage is dependent on surface expression of annexin II. Blood. 2001;97:777–84.CrossRefPubMed

16.

Brownstein C, Deora AB, Jacovina AT, Weintraub R, Gertler M, Khan KM, et al. Annexin II mediates plasminogen-dependent matrix invasion by human monocytes: enhanced expression by macrophages. Blood. 2004;103:317–24.CrossRefPubMed

17.

Hayashi T, Morishita E, Ohtake H, Oda Y, Ohta K, Arahata M, et al. Expression of annexin II in human atherosclerotic abdominal aortic aneurysms. Thromb Res. 2008;123(2):274–80.CrossRefPubMed

18.

Anidjar S, Salzmann JL, Gentric D, Lagneau P, Camilleri JP, Michel JB. Elastase-induced experimental aneurysms in rats. Circulation. 1990;82:973–81.CrossRefPubMed

19.

Hance KA, Tataria M, Ziporin SJ, Lee JK, Thompson RW. Monocyte chemotactic activity in human abdominal aortic aneurysms: role of elastin degradation peptides and the 67-kD cell surface elastin receptor. J Vasc Surg. 2002;35:254–61.CrossRefPubMed

20.

Pyo R, Lee JK, Shipley JM, Curci JA, Mao D, Ziporin SJ, et al. Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. J Clin Invest. 2000;105:1641–9.CrossRefPubMedPubMedCentral

21.

Yamaguchi T, Yokokawa M, Suzuki M, Higashide S, Katoh Y, Sugiyama S, et al. The effect of immunosuppression on aortic dilatation in a rat aneurysm model. Surg Today. 2000;30:1093–9.CrossRefPubMed

22.

Steins MB, Padro T, Li CX, Mesters RM, Ostermann H, Hammel D, et al. Overexpression of tissue-type plasminogen activator in atherosclerotic human coronary arteries. Atherosclerosis. 1999;145:173–80.CrossRefPubMed

23.

Anidjar S, Dobrin PB, Eichorst M, Graham GP, Chejfec G. Correlation of inflammatory infiltrate with the enlargement of experimental aortic aneurysms. J Vasc Surg. 1992;16:139–47.CrossRefPubMed

24.

Yamaguchi T, Yokokawa M, Suzuki M, Higashide S, Katoh Y, Sugiyama S, et al. The time course of elastin fiber degeneration in a rat aneurysm model. Surg Today. 2000;30:727–31.CrossRefPubMed

25.

Ling Q, Jacovina AT, Deora A, Febbraio M, Simantov R, Silverstein RL, et al. Annexin II regulates fibrin homeostasis and neoangiogenesis in vivo. J Clin Invest. 2004;113:38–48.CrossRefPubMedPubMedCentral

Title: Expression of annexin II in experimental abdominal aortic aneurysms
Authors: Tomoe Hayashi
Eriko Morishita
Hiroshi Ohtake
Yoshio Oda
Hidesaku Asakura
Shinji Nakao
Publication date: 01-10-2009
Publisher: Springer Japan
Published in: International Journal of Hematology / Issue 3/2009
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI: https://doi.org/10.1007/s12185-009-0410-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2009

Donor cell-derived acute lymphocytic leukemia after allogeneic stem cell transplantation for multiple myeloma

Recurrent extramedullary relapse of acute myelogenous leukemia after allogeneic hematopoietic stem cell transplantation in a patient with the chromosomal abnormality t(8;21) and CD56-positivity

HHV8-positive, HIV-negative multicentric Castleman’s disease: early and sustained complete remission with rituximab therapy without reactivation of Kaposi sarcoma

Primary cutaneous anaplastic large cell lymphoma of the vulva: a typical cutaneous lesion with an ‘atypical’ presenting site

Successful allogeneic bone marrow transplantation for myelodysplastic syndrome complicated by severe pulmonary alveolar proteinosis

Prospective analysis of clinical and cytogenetic features of 435 cases of MDS diagnosed using the WHO (2001) classification: a prognostic scoring system for predicting survival in RCMD

Keynote webinar | Spotlight on antibody–drug conjugates in cancer